Home | Publications | Diseases | CNS place holder
place holder place holder

CNS

The CNS Market Outlook to 2013

Competitive landscape, pipeline analysis and growth opportunities

Publication Date   September 2008
Publisher   Business Insights
Product Type   Report
Pages   231
ISBN Number   not applicable
Product Code   RBI00184
Ask a question about this product?

Price £1,995.00

approximately: $2,915 | €2,186

Summary


The CNS disorders market is one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms continue to be favorable within the area, despite the relatively high risks associated with product development. This is largely due to significant levels of unmet medical need and the clinical specificity of many CNS drugs. High levels of investment have contributued to a rich product pipeline, with an estimated 600 clinical candidates currently under development, and companies are widely engaged in licensing novel/clinically differentiated CNS products. The sector has struggled recently however, with previously dominant product classes coming under increasing pressure from generic competition and safety concerns.

The CNS Market Outlook to 2013 is a new report published by Business Insights that provides comprehensive coverage of the major markets within the global CNS disorders market, incorporating a detailed epidemiological analysis of major indications and key factors impacting their prevalence. This report profiles the factors and underlying trends shaping the market landscape and identifies the most promising areas of potential growth.

Current leading brands of treatment within each indication are assessed and ten of the market's leading players are profiled. Sales forecasts for currently marketed and key pipeline products over the 2008-13 period are also provided. Discover the key trends and growth drivers of the CNS market, assess the competitive dynamics of leading companies and evaluate the future prospects of pipeline products with this new report.

Content


  • The CNS Market Outlook to 2013
  • Executive Summary
  • Overview and epidemiology of CNS disorders
  • Global market analysis
  • Pipeline analysis
  • Competitive landscape
  • Chapter 1 Scope and methodology
    • Scope
    • Methodology
  • Chapter 2 Overview and epidemiology of
    • CNS disorders
    • Summary
    • Introduction
    • Schizophrenia
    • Overview
    • Epidemiology
    • Forecast epidemiology
    • Major depressive disorder
    • Overview
    • Epidemiology
    • Forecast epidemiology
    • Epilepsy
    • Overview
    • Epidemiology
    • Forecast epidemiology
    • Alzheimer''s disease
    • Overview
    • Epidemiology
    • Forecast epidemiology
    • iv
    • Insomnia
    • Overview
    • Epidemiology
    • Epidemiology
    • Parkinson''s disease
    • Overview
    • Epidemiology
    • Forecast epidemiology
    • Migraine
    • Overview
    • Epidemiology
    • Forecast epidemiology
    • Attention-deficit hyperactivity disorder
    • Overview
    • Epidemiology
  • Chapter 3 Global market analysis
    • Summary
    • Introduction
    • Market analysis by country
    • Licensing trends
    • Market analysis by indication
    • Leading brand dynamics
    • Key events in the CNS disorder market
    • Launch of first transdermal patch formulation of Novartis'' Exelon
    • for the treatment of AD
    • Once-Daily and long acting stimulants remain the gold standard in
    • the treatment of ADHD
    • Disappointing clinical results from bapineuzumab
    • Recall of Neupro in the US due to manufacturing problems
    • Spheramine fails to demonstrate efficacy in Phase IIb Parkinson's
    • disease study
    • GLP-1 may treat Parkinson''s disease
    • Acetyl cholinesterase inhibitors to remain the mainstay treatment
    • option for AD
    • Newer therapies in epilepsy prove efficacious in multiple CNS
    • disorder indications
    • FDA orders warning labels for antipsychotic drugs
    • Newer agents continue to dominate antipsychotic market
    • Label expansions for SSRIs provides an opportunity for growth and
    • differentiation
    • Schizophrenia
    • Market analysis
    • Leading brands in the schizophrenia market
    • v
    • Atypical antipsychotics
    • Key brand analysis
    • Schizophrenia sales forecast to 2013
    • Major depressive disorder (MDD)
    • Market analysis
    • Leading brands in the antidepressants market
    • Selective Serotonin Reuptake inhibitors
    • Market Dynamics
    • Key brand analysis
    • Selective Norepinephrine Reuptake Inhibitors
    • Market Dynamics
    • Key brand analysis
    • Antidepressants sales forecast to 2013
    • Epilepsy
    • Market analysis
    • Leading brands in the anti-epileptic market
    • Second generation anti-epileptics
    • Key brand analysis
    • Anti-epilepsy sales forecast to 2013
    • Alzheimer''s disease
    • Market analysis
    • Leading brands in the anti-Alzheimer''s market
    • Cholinesterase inhibitors market analysis
    • Market analysis
    • Key brand analysis
    • NMDA receptor antagonists market analysis
    • Key brand analysis
    • Anti-Alzheimer''s sales forecast to 2013
    • Insomnia
    • Market analysis
    • Non-benzodiazepines
    • Key brand analysis
    • Anti-insomnia sales forecast to 2013
    • Parkinson''s disease (PD)
    • Market analysis
    • Leading brands in the anti-parkinson''s market
    • COMT inhibitors
    • Key brand analysis
    • Dopamine agonists
    • Key brand analysis
    • Mono-amino oxidase (MAO) inhibitors
    • Key brand analysis
    • Anti-parkinson''s sales forecast to 2013
    • Migraine
    • Market analysis
    • Leading brands in the anti-migraine market
    • Triptans
    • Key brand analysis
    • Anti-migraine sales forecast to 2013
    • vi
    • Attention-deficit hyperactivity disorder (ADHD)
    • Market analysis
    • Leading brands in the ADHD market
    • Stimulants
    • Key brand analysis
    • Non-stimulants
    • Key brand analysis
    • ADHD sales forecast to 2013
    • Total CNS disorders'' sales forecast
  • Chapter 4 Pipeline analysis
    • Summary
    • Introduction
    • Key trends in R & D
    • Disease modifying agents hold promise in AD
    • Novel drugs with differentiated profiles represent a sizeable market
    • opportunity
    • New drug delivery formulations confer a competitive advantage
    • Combination drugs demonstrate advantages over individual components
    • CNS disorders pipeline
    • Leading drugs in development
    • Profiles of key pipeline products
    • Recently marketed drugs
    • Invega
    • Pristiq
    • Treximet
    • Vyvanse
    • Drugs in registration
    • Asenapine
    • Inovelon
    • Paliperidone Palmitate
    • Vimpat
    • Drugs in phase III clinical studies
    • Almorexant (ACT-078573)
    • Amibegron (SR-58611)
    • Bapineuzumab (AAB-001)
    • Eplivanserin (SR-46349)
    • Saredutant (SR-48968)
    • Semagacestat (LY-450139)
    • Telcagepant (MK-0974)
    • Pipeline forecast
    • vii
  • Chapter 5 Competitive landscape
    • Summary
    • Introduction
    • Sales performance of leading players
    • Detailed analysis of leading CNS players
    • Johnson & Johnson (J&J)
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Eli Lilly
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • Marketed product portfolio: Strattera
    • R&D pipeline analysis
    • Strategic and growth analysis
    • GlaxoSmithKline (GSK)
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Pfizer
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • AstraZeneca
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Novartis
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Sanofi-Aventis
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • viii
    • Wyeth
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Forest
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Eisai
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
  • Chapter 6 Appendix
    • IMS Data
    • N2C - Anti-Migraine preparations
    • N3A - Anti-Epileptics
    • N4A - Anti-Parkinson drugs
    • N5A - Antipsychotics
    • N5B - Hypnotics/Sedatives
    • N6A - Antidepressants
    • N6B - Psychostimulants
    • N7D - Anti-Alzheimer''s products
    • N7X - Other CNS drugs
    • Glossary
    • AD Assessment Scale cognition; (ADAS-cog)
    • ADHD-RS
    • Clinical Dementia Rating (CDR) scale
    • HAM-D17
    • Mini Mental State Exam (MMSE)
    • Neuropsychological Test Battery (NTB)
    • Personal and Social Performance Scale (PSP)
    • Positive and Negative Syndrome Scale for schizophrenia (PANSS)
  • List of Figures
    • Figure 2.1: Schizophrenia: classification of symptoms
    • Figure 2.2: Typical treatment patterns in the treatment of schizophrenia
  • ix
    • Figure 2.3: Different forms of epilepsy
    • Figure 2.4: Different stages of Alzheimer''s disease
    • Figure 2.5: Typical treatment patterns in the treatment of Alzheimer''s disease
    • Figure 2.6: Typical treatment patterns in the treatment of migraine
    • Figure 3.7: Global CNS market share by geography, 2007
    • Figure 3.8: Sales of types of CNS disorder brands, 2006-2007
    • Figure 4.9: Key trends in the R&D of CNS disorders, 2008
    • Figure 4.10: Leading recently launched products and late-stage R&D compounds indicated for the
  • treatment of CNS disorders, 2008
    • Figure 5.11: Market share of key players by sales value, 2007
    • Figure 5.12: Projected market share of key players by sales value, 2013
    • Figure 5.13: Market share and ranking of leading players in the global CNS disorders market,
  • 2007-2013
    • Figure 5.14: J&J''s CNS portfolio sales by indication, 2007
    • Figure 5.15: Eli Lilly''s CNS portfolio sales by indication, 2007
    • Figure 5.16: GSK''s CNS portfolio sales by indication, 2007
    • Figure 5.17: Pfizer''s CNS portfolio sales by indication, 2007
    • Figure 5.18: AstraZeneca''s portfolio sales by indication, 2007
    • Figure 5.19: Novartis'' portfolio sales by indication, 2007
    • Figure 5.20: Sanofi-Aventis'' portfolio sales by indication, 2007
    • Figure 5.21: Wyeth''s portfolio sales by indication, 2007
    • Figure 5.22: Forest''s portfolio sales by indication, 2007
    • Figure 5.23: Eisai''s portfolio sales by indication, 2007
  • x
    • Table 2.1: Estimated prevalence of CNS disorders across the seven major
    • Table 2.2: Estimated prevalence of schizophrenia across the seven major markets, 2007
    • Table 2.3: Forecast epidemiology of schizophrenia across the seven major markets, 2007-2013
    • Table 2.4: Estimated prevalence of MDD across the seven major markets, 2007
    • Table 2.5: Estimated prevalence of MDD across the seven major markets, 2007
    • Table 2.6: Estimated prevalence of epilepsy across the seven major markets, 2007
    • Table 2.7: Forecast epidemiology of epilepsy across the seven major markets, 2007-2013
    • Table 2.8: Estimated prevalence of Alzheimer's disease across the seven major markets, 2007
    • Table 2.9: Forecast epidemiology of AD across the seven major markets, 2007-2013
    • Table 2.10: Estimated prevalence of insomnia across the seven major markets, 2007
    • Table 2.11: Estimated prevalence of Parkinson's disease across the seven major markets, 2007
    • Table 2.12: Estimated prevalence of Parkinson's disease across the seven major markets, 2007
    • Table 2.13: Estimated prevalence of migraine across the seven major markets, 2007
    • Table 2.14: Forecast epidemiology of migraine across the seven major markets, 2007-2013
    • Table 2.15: Estimated prevalence of ADHD in adults across the seven major markets, 2008
    • Table 2.16: Estimated prevalence of ADHD in children across the seven major markets, 2008
    • Table 3.17: Breakdown of the global CNS market by drug class, $m, 2006-2007
    • Table 3.18: Leading brands in the global CNS market, $m, 2006-2007
    • Table 3.19: Breakdown of the global schizophrenia market by drug class, $m, 2006-2007
    • Table 3.20: Leading antipsychotic medications in the CNS market, $m, 2006-2007
    • Table 3.21: Antipsychotic products sales forecast, $m, 2007-2013
    • Table 3.22: Breakdown of the global antidepressant market by drug class, $m, 2006-2007
    • Table 3.23: Leading antipsychotic medications in the CNS market, $m, 2006-2007
    • Table 3.24: Leading SSRIs in the MDD market, $m, 2006-2007
    • Table 3.25: Leading SNRIs in the MDD market, $m, 2006-2007
    • Table 3.26: Antidepressants sales forecast, $m, 2007-2013
    • Table 3.27: Global epilepsy market, $m, 2006-2007
    • Table 3.28: Leading anti-epileptic medications in the CNS market, $m, 2006-2007
    • Table 3.29: Anti-epileptics sales forecast, $m, 2007-2013
    • Table 3.30: Breakdown of the global anti-alzheimer''s market by drug class, $m, 2006-2007
    • Table 3.31: Leading anti-alzheimer drugs in the global CNS market by drug class, $m, 2006-2007
    • Table 3.32: Leading cholinesterase inhibitors in the global anti-alzheimer''s market by drug class,
  • $m, 2006-2007
    • Table 3.33: Leading NMDA receptor antagonists in the global anti-alzheimer''s market by drug
  • class, $m, 2006-2007
    • Table 3.34: Anti-alzheimer's products sales forecast, $m, 2007-2013
    • Table 3.35: Breakdown of the global insomnia market by drug class, $m, 2006-2007
    • Table 3.36: Leading insomnia drugs in the global CNS market by drug class, $m, 2006-2007
    • Table 3.37: Anti-insomnia products sales forecast, $m, 2007-2013
    • Table 3.38: Global anti-parkinson''s disease market, $m, 2006-2007
    • Table 3.39: Leading anti-parkinson drugs in the global CNS market by drug class, $m, 2006-2007
    • Table 3.40: Anti-parkinson drugs sales forecast, $m, 2007-2013
    • Table 3.41: Breakdown of the global anti-migraine market by drug class, $m, 2006-2007
    • Table 3.42: Leading anti-migraine medications in the CNS market, $m, 2006-2007
  • xi
    • Table 3.43: Anti-migraine products sales forecast, $m, 2007-2013
    • Table 3.44: Breakdown of the global ADHD market by drug class, $m, 2006-2007
    • Table 3.45: Leading ADHD medications in the CNS market, $m, 2006-2007
    • Table 3.46: Anti-ADHD products sales forecast, $m, 2007-2013
    • Table 3.47: CNS Market sales forecast by drug class, $m, 2007-2013
    • Table 4.48: CNS pipeline by indication and stage of development, 1H2008
    • Table 4.49: An overview of Invega
    • Table 4.50: An overview of Pristiq
    • Table 4.51: An overview of Treximet
    • Table 4.52: An overview of Vyvanse
    • Table 4.53: An overview of Asenapine
    • Table 4.54: An overview of Inovelon
    • Table 4.55: An overview of Paliperidone Palmitate
    • Table 4.56: An overview of Vimpat
    • Table 4.57: An overview of Almorexant (ACT-078573)
    • Table 4.58: An overview of Amibegron (SR-58611)
    • Table 4.59: An overview of Bapineuzumab (AAB-001)
    • Table 4.60: An overview of Eplivanserin (SR-46349)
    • Table 4.61: An overview of Saredutant (SR-48968)
    • Table 4.62: An overview of Semagacestat (LY-450139)
    • Table 4.63: An overview of Telcagepant (MK-0974)
    • Table 4.64: CNS disorders pipeline forecast, 2008-2013 ($m)
    • Table 5.65: Leading players in the global CNS disorders market, 2007-2013 ($m)
    • Table 5.66: J&J''s CNS product portfolio, 2006-2007
    • Table 5.67: J&J''s CNS R&D product pipeline, 2007
    • Table 5.68: Eli Lilly''s CNS product portfolio, 2006-2007
    • Table 5.69: Eli Lilly's CNS R&D product pipeline, 2007
    • Table 5.70: GSK''s CNS product portfolio, 2006-2007
    • Table 5.71: GSK's CNS R&D product pipeline, 2007
    • Table 5.72: Pfizer''s CNS product portfolio, 2006-2007
    • Table 5.73: Pfizer's CNS R&D product pipeline, 2007
    • Table 5.74: AstraZeneca''s CNS product portfolio, 2006-2007
    • Table 5.75: AstraZeneca's CNS R&D product pipeline, 2007
    • Table 5.76: Novartis'' CNS product portfolio, 2006-2007
    • Table 5.77: Novartis' CNS R&D product pipeline, 2007
    • Table 5.78: Sanofi-Aventis'' CNS product portfolio, 2006-2007
    • Table 5.79: Sanofi-Aventis' CNS R&D product pipeline, 2007
    • Table 5.80: Wyeth''s CNS product portfolio, 2006-2007
    • Table 5.81: Wyeth's CNS R&D product pipeline, 2007
    • Table 5.82: Forest''s CNS product portfolio, 2006-2007
    • Table 5.83: Forests' CNS R&D product pipeline, 2007
    • Table 5.84: Eisai''s CNS product portfolio, 2006-2007
    • Table 5.85: Eisai's CNS R&D product pipeline, 2007